[Antiplatelet therapy in cardiac diseases]

Area of Science:

• Cardiology
• Pharmacology
• Vascular Medicine

Context:

• Aspirin is a widely used antiplatelet medication.
• Cardiovascular diseases remain a leading cause of mortality worldwide.
• Understanding the efficacy of aspirin in various cardiovascular conditions is crucial for clinical practice.

Purpose:

• To summarize the established role of aspirin in managing myocardial infarction (MI), angina pectoris, and post-procedural care for coronary artery bypass grafting (CABG) and percutaneous transluminal coronary angioplasty (PTCA).

Summary:

• Aspirin (160-300 mg/day) initiated immediately post-myocardial infarction (MI) reduces mortality and reinfarction, with maintenance therapy recommended.
• For unstable angina, aspirin (300 mg/day for 2 years) lowers mortality and MI incidence; ticlopidine shows some benefit for angina at rest.
• Post-CABG, aspirin (325 mg/day) combined with dipyridamole is advised. For PTCA, antiplatelet drugs prevent acute occlusion but not late restenosis.

Impact:

• This information supports the use of aspirin as a cornerstone therapy in preventing thrombotic events across a spectrum of cardiovascular conditions.
• Optimized aspirin regimens can improve patient outcomes and reduce the risk of recurrent cardiovascular events.
• Further research may explore novel antiplatelet strategies for conditions like late restenosis post-PTCA.